Jenkins Suggests "Complete Response" Letter Transparency Could Prompt Better Drug Applications, Faster Reviews

If FDA's transparency initiative results in the public release of "complete response" letters, Office of New Drugs Director John Jenkins sees a possible side benefit for the agency